AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

QIAGEN N.V. to Report Fourth Quarter and Full Year 2019 Results

January 10, 2020 GMT

VENLO, the Netherlands--(BUSINESS WIRE)--Jan 10, 2020--

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans as previously announced to release its report on results for the fourth quarter and full-year 2019 on Tuesday, February 4, at approximately 22:05 Central European Time (CET) / 16:05 Eastern Standard Time (EST).

A conference call is planned for Wednesday, February 5, at 15:00 CET / 9:00 EST hosted by Thierry Bernard, Senior Vice President, Head of Molecular Diagnostics Business Area, and Interim CEO, and Roland Sackers, Chief Financial Officer.

Conference call and webcast details

The conference call will begin at 15:00 CET / 9:00 EST on Wednesday, February 5, 2020.

Interested parties may listen to the call by dialing:

+1 646 828 8193 (U.S.), +44 (0)330 336 9126 (UK), +49 (0)69 2222 25575 (Germany).

To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.

Conference ID: 2139086

The webcast will be accessible at:

https://globalmeet.webcasts.com/starthere.jsp?ei=1279315&tp_key=b4903b138d

A conference call replay will be available by using the following link:

https://globalmeet.webcasts.com/starthere.jsp?ei=1279315&tp_key=b4903b138d

Contact: IR@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide.

Further information can be found at http://www.qiagen.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200110005174/en/

CONTACT: John Gilardi

Vice President Corporate Communications and Investor Relations

+49 2103 29 11711

+1 240 686 2222

Email:ir@qiagen.com

Phoebe Loh

Associate Director Investor Relations

+49 2103 29 11457

Email:ir@qiagen.com

KEYWORD: NETHERLANDS EUROPE

INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL DEVICES HEALTH SCIENCE RESEARCH

SOURCE: QIAGEN N.V.

Copyright Business Wire 2020.

PUB: 01/10/2020 05:17 AM/DISC: 01/10/2020 05:17 AM

http://www.businesswire.com/news/home/20200110005174/en